It is inspiring that the first clinical trial, designed to assess the clinical benefit and safety of the SGLT-2 inhibitor, revealed the cardiovascular benefits of dapagliflozin in patients with CAVD undergoing TAVR. This evidence concerns the gene SLC5A2 and congenital bilateral aplasia of vas deferens from CFTR mutation.